WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

Disc Medicine, Inc., a biopharmaceutical company focused on treatments for hematologic diseases, announced positive feedback from its pre-New Drug Application (NDA) meeting with the FDA regarding its ...

Disc Medicine, Inc. (IRON) closed the last trading session at $82.14, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional ...

Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will ...

Disc Medicine sees its Relative Strength Rating enter the 80-plus level.

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National ...

Disc Medicine (IRON) has drawn fresh attention after securing priority FDA review for bitopertin and outlining commercialization plans, while also advancing DISC-0974 and DISC-3405 through ongoing ...

The chief legal officer of Disc Medicine sold 6,500 shares of the company for $511,472 on Jan. 2. The sale represented 14.68% of Khara's direct holdings, as reported at the time, reducing his direct ...